ExodusPoint Capital Management LP Acquires 12,332 Shares of Haemonetics Co. (NYSE:HAE)

ExodusPoint Capital Management LP lifted its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 32.5% in the first quarter, according to its most recent filing with the SEC. The firm owned 50,232 shares of the medical instruments supplier's stock after acquiring an additional 12,332 shares during the period. ExodusPoint Capital Management LP owned approximately 0.10% of Haemonetics worth $4,157,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Natixis Advisors L.P. bought a new position in shares of Haemonetics during the 1st quarter worth about $1,079,000. Envestnet Asset Management Inc. increased its position in shares of Haemonetics by 1,335.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 406,531 shares of the medical instruments supplier's stock worth $2,091,000 after purchasing an additional 378,219 shares in the last quarter. Harvest Fund Management Co. Ltd increased its position in shares of Haemonetics by 185.8% during the 1st quarter. Harvest Fund Management Co. Ltd now owns 1,349 shares of the medical instruments supplier's stock worth $112,000 after purchasing an additional 877 shares in the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Haemonetics during the 1st quarter worth about $207,000. Finally, Vise Technologies Inc. increased its position in shares of Haemonetics by 22.5% during the 1st quarter. Vise Technologies Inc. now owns 5,218 shares of the medical instruments supplier's stock worth $432,000 after purchasing an additional 960 shares in the last quarter. 99.38% of the stock is owned by institutional investors.

In other news, EVP Josep Llorens sold 4,928 shares of the business's stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $90.00, for a total value of $443,520.00. Following the completion of the sale, the executive vice president now owns 18,463 shares of the company's stock, valued at $1,661,670. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.79% of the stock is currently owned by company insiders.

NYSE:HAE opened at $88.42 on Tuesday. Haemonetics Co. has a one year low of $71.63 and a one year high of $95.26. The company has a market cap of $4.48 billion, a P/E ratio of 33.37, a P/E/G ratio of 2.32 and a beta of 0.42. The firm's fifty day moving average price is $88.05 and its two-hundred day moving average price is $84.34. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.38 and a quick ratio of 2.16.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The medical instruments supplier reported $1.05 EPS for the quarter, beating the consensus estimate of $0.73 by $0.32. The firm had revenue of $311.30 million for the quarter, compared to the consensus estimate of $292.74 million. Haemonetics had a net margin of 11.21% and a return on equity of 22.49%. The company's quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.58 earnings per share. Equities analysts expect that Haemonetics Co. will post 3.82 earnings per share for the current year.

HAE has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Haemonetics from a "buy" rating to a "strong-buy" rating in a research report on Friday. JMP Securities lifted their price target on shares of Haemonetics from $105.00 to $115.00 in a research report on Friday, May 12th. Finally, Barrington Research lifted their price target on shares of Haemonetics from $111.00 to $114.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 9th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $103.67.

Check Out Our Latest Report on HAE

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Haemonetics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.

While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.